Activation of carrier proteins for conjugation with sulfhydryl-containing haptens.
Maleimide activated BSA carrier protein was purchased from Sigma Chemical (St Louis, MO).
The manufacturer reported that approximately 16 sulfhydryl sites per protein molecule were available for conjugation. For activation reactions of IC KLH , 2 mg of Sulfo-SMCC (No-Weigh Sulfo-SMCC, Thermo Fisher Scientific, Rockford, IL, cat no. PI22622) was solubilized in 200 μL distilled water by gentle agitation with mild heat (~40 °C), and diluted to 2.5 mg/mL final concentration with conjugation buffer (50mM NaPO4, 0.1M EDTA, 0.9M NaCl, 5% lactose, pH 7.5). A 200 molar excess of Sulfo-SMCC was added to IC KLH in conjugation buffer for a final IC KLH concentration of 2 mg/mL in 2 mL and stirred at room temperature for 1 hr. The activated IC KLH solution was desalted using 5 mL Zeba Spin Protein Desalting Columns (Thermo Fisher Scientific) and 50 μg aliquots were removed for radiometric assays.
Sulfhydryl reduction reaction.
Prior to conjugation, the SSMO9 hapten dimer was reduced with three-fold greater concentrations of Tris (2-carboxyethyl)phosphine (TCEP, Figure 1 'Reduction' step). For radiometric analysis of hapten incorporation, 14 C-Cystine (~420,000 DPM in 10 µL, provided as L-cystine [3,3'-14 C] specific activity 107 Ci/mol; Perkin Elmer, Waltham, MA), plus either unlabeled cysteine or METH-SSMO9 hapten were mixed with three-fold greater concentrations of TCEP. This is an important aspect of the conjugation scheme, since unlike reducing agents such as dithiothreotal and 2-mercaptoethanol, TCEP does not contain sulfhydryl groups that can react with the maleimide group of Sulfo-SMCC and compete for hapten conjugation sites.
Although both dimer and monomer forms of the reactants were used, all stock solutions and calculations were made consistent based on the average monomeric mass values. The final volumes of the reduction reactions for radiometric analysis, MALDI-TOF analysis, and vaccine production were 110, 125, and 600 µL, respectively. For a summary of concentrations and molar ratios see Table 1 . All reduction reactions were conducted for 2 hrs at 22 °C with shaking 3. Conjugation of sulfhydryl-containing molecules to maleimide activated proteins.
Molar ratios of maleimide activated BSA to SMO9, SMO9 plus 14 C-Cys, or cysteine plus 14 CCys in the final conjugation reaction were 1:10, 1:15, 1:20, and 1:30, respectively. The molar ratio was approximately 1:50 in the activated IC KLH reaction.
Briefly, sulfhydryl-containing reduction products were added slowly to the activated carrier proteins while gently mixing followed by 2 hrs of incubation with mixing. To avoid unwanted oxidation of sulfhydryl groups, all reactions and procedures were performed under an overlay of argon gas and with argon bubbled conjugation buffer. After conjugation was complete, any unreacted maleimide groups of the BSA-SMO9 or IC KLH -SMO9 vaccine were blocked or end capped by the addition of a four-fold excess of cysteine. This step was a precaution to prevent any potential chemical reactions of the vaccine with proteins in vivo. Final reaction volumes for radiometric analysis, MALDI-TOF analysis, and vaccine production conjugations were 100, 525, and 2500 µL, respectively. The final BSA concentration in the products for radiometric and MALDI-TOF analysis were 7.6 and 5.8 µM, respectively. The final concentrations of IC KLH used for radiometric analysis and vaccine production were 1.3 and 4 µM, respectively.
For each radiometric analysis reaction, a 10 µL aliquot of the 100 µL total volume was removed and added to 4 mL scintillation fluid to determine the total concentration of 14 C-Cys tracer. The remaining 90 µL of each reaction was precipitated with 500 µL ice cold 20% 4 trichloroacetic acid for 1 hr on ice and centrifuged at 14,000 x g for 10 min, before removal of the supernatant. The pellet was then washed with 20% trichloroacetic acid and centrifuged at 14,000 x g for 5 min. The supernatant was removed and the pellet was resuspended in 1.5 mL scintillation fluid (Ecoscint A, National Diagnostics, Atlanta, GA). The 14 C-Cys concentration in the resuspended pellet and the previously collected 10 µL aliquot for determination of total radioactivity were then measured in scintillation fluid by liquid scintillation spectrophotometry.
The number of conjugated sites were determined by multiplying the percent total cysteine incorporated (as measured by 14 C-Cys -equivalents) by the known molar excess of hapten or cysteine to BSA by the following equation: pellet DPM / (pre-precipitation solution aliquot DPM x 9) x nmol cysteine / nmol activated BSA. Note that the calculation of total 14 C-Cys content was multiplied by 9 rather than 10 to account for the use of 10% of the sample to measure total 14 CCys content.
Gel analysis of hapten-protein conjugates.
For Western blot confirmation of BSA hapten conjugation with SMO9, gels were transferred to nitrocellulose membranes and blocked overnight. The blots were then incubated with the primary detection antibody (anti-METH monoclonal antibody mAb4G9) for two hours to allow detection of METH-like haptens on the protein conjugates. The blots were then washed, followed by the addition of a secondary anti-mouse IgG specific antibody conjugated to horseradish peroxidase (Sigma Chemical, Cat. #A9917). Both antibodies were diluted 1:5000 in 0.2% BSA in Trisbuffered saline with Tween 20. Visualization of specific antibody binding was performed using the Millipore Immobilon Western Chemiluminescent HRP Substrate Kit (EMD-Millipore, Billerica, MA).
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For IC KLH analysis, an agarose gel system (APE, Fluorescent LP-Next Gel system, Amresco, Salon, OH) was used. Briefly, a 1% SDS-agarose mini-gel was run at 50 volts for 80 min, then exposed to UV light for 3 min to visualize and document the fluorescently labeled protein conjugates. The gel was transferred to an Immobilon-NC (EMD-Millipore) membrane for 1 hr at 25 V constant voltage using a vertical transfer tank system and Rapid Transfer Buffer (Amresco LLC, Solon, OH). Western blot detection was performed as described for BSAconjugated haptens. 
